Abrilada

Abrilada is a biosimilar medication to adalimumab, which is used to treat various autoimmune diseases. It is produced by Pfizer and is designed to be similar in terms of safety, efficacy, and quality to the original biologic drug, Humira.

Medical Uses

Abrilada is prescribed for the treatment of several autoimmune conditions, including:

• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn's disease
• Ulcerative colitis
• Plaque psoriasis

Mechanism of Action

Abrilada works by inhibiting tumor necrosis factor (TNF), a substance in the body that causes inflammation in autoimmune diseases. By blocking TNF, Abrilada helps reduce the inflammatory response and alleviate symptoms associated with these conditions.

Approval and Regulation

Abrilada has been approved by various regulatory agencies, including the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in the European Union. The approval process for biosimilars like Abrilada involves demonstrating that the biosimilar is highly similar to the reference product, with no clinically meaningful differences in terms of safety, purity, and potency.

Administration

Abrilada is administered via subcutaneous injection. The dosage and frequency of administration depend on the specific condition being treated and the patient's response to the medication.

Side Effects

Common side effects of Abrilada include:

• Injection site reactions
• Upper respiratory infections
• Headache
• Rash

Serious side effects may include:

• Serious infections
• Malignancies
• Hepatitis B reactivation
• Heart failure

Related Pages

• Adalimumab
• Biosimilar
• Autoimmune disease
• Pfizer
• Humira
• Tumor necrosis factor